Le Lézard
Classified in: Health
Subjects: POL, TRD, AVO

3 Reasons Innovation Depends On Strong IP Protections in the TPP



WASHINGTON, June 16, 2015 /PRNewswire-USNewswire/ -- As Congress continues to debate Trade Promotion Authority (TPA), it is important to keep in mind why the Trans-Pacific Partnership (TPP) ? the largest trade deal in history ? can and should help propel the United States (U.S.) into a new era of innovation and productivity in biopharmaceutical manufacturing.

3 Reasons Innovation Depends on Strong IP Protections in the TPP

Our industry's core mission is the discovery of new treatments and cures to help patients live longer, healthier lives. Below are three important facts to keep in mind about why upholding strong intellectual property (IP) protections as part of TPP are vital to the continued discovery and delivery of medicines for the world's patients:

#1. Creating life-saving medicines requires significant investment and resources. 
New medicines are the result of up to 15 years of complex research and development at an average cost of $2.6 billion. The U.S. and other nations must encourage and incentivize the innovation that has the potential to propel today's research into tomorrow's most cutting-edge treatments and cures.

#2. For medical innovation to continue, the TPP must uphold the strong IP protections that currently exist in the U.S. 
The important role of IP ? including a 12-year data protection period for biologics ? is not a new idea. In fact, it was codified in the Affordable Care Act, endorsed by a strong, bipartisan majority in Congress. 

#3. The evidence is overwhelming that the U.S. model works. 
Strong protection of IP is a catalyst for the creation of new medicines for the world's patients. In too many countries, patient access to medicines are stymied not by strong IP protections, but dynamics like poor infrastructure, lack of investment and high tariffs.  The robust IP protections afforded in the United States have helped foster a system whereby the U.S. dominates the pipeline of new drugs in development and, in turn, where generics comprise a healthy 85 percent-plus of the market.

As PhRMA CEO John Castellani notes this week in Morning Consult, we must continue to create an environment ripe for investment today to unlock the promising science of tomorrow. 

This post originally appeared here: http://catalyst.phrma.org/3-reasons-innovation-depends-on-strong-ip-protections-in-the-tpp.

Contact: Tina Stow; 202-835-3460; newsroom@phrma.org

Pharmaceutical Research and Manufacturers of America.

Photo - http://photos.prnewswire.com/prnh/20150616/223597

Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO

 

SOURCE Pharmaceutical Research and Manufacturers of America


These press releases may also interest you

at 20:33
Assure Holdings Corp. (the "Company" or "Assure") , a provider of intraoperative neuromonitoring services, reported financial results for the three months ended March 31, 2018, and revised results for the three months ended...

at 20:00
EAGAN, Minn., Aug. 17, 2018 /PRNewswire-PRWeb/ -- Charles E. Crutchfield III, MD, and Crutchfield Dermatology (Eagan, Minnesota) recently assisted the veterinary staff with a unique patient, Haps, a sand tiger shark, to help with his scoliosis...

at 19:35
NASHVILLE, Tenn., Aug. 17, 2018 /PRNewswire-PRWeb/ -- Tinnitus 911 recently announced their commitment to raising awareness for orphaned children around the globe. The PhytAge Laboratories supplement company will soon launch their new website,...

at 19:00
QUEENS, N.Y., Aug. 17, 2018 /PRNewswire-PRWeb/ -- Many people make the mistake of neglecting their dental oral hygiene, because they're busy, distracted, or just really tired at night. While you might think that you are getting away with it if you...

at 18:30
Disseminating medical information to external stakeholders such as physicians and payers is an important activity that has to be done right the first time. And just as pharmaceutical companies differ in which external groups they focus on for...

at 17:33
Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") today announced that the Company has elected to issue 5,657,957 common shares of the Company ("Common Shares") to The Salzman Group in payment of invoices issued under the payments agreement...




News published on 16 june 2015 at 17:35 and distributed by: